2020 Archives - Ryvu Therapeutics

January 4, 2021

The new Clinical Trial Application for the conduct of a Phase I/II study of RVU120 (SEL120) in patients with solid tumors submitted by Ryvu Therapeutics S.A.

Read More

December 1, 2020

Three Posters on SEL24/MEN1703 including Pharmacodynamic Data from the Dose Escalation Part of DIAMOND-01 Trial to be published at American Society of Hematology (ASH) Annual Meeting

Read More

November 23, 2020

Appointment of the new Management Board Member of Ryvu Therapeutics S.A.

Read More

November 19, 2020

Ryvu Therapeutics S.A. Q3 2020 Financial Report

Read More

October 21, 2020

Revision of the Company’s research project pipeline

Read More

October 14, 2020

Ryvu Therapeutics abstract concerning the STING program accepted for presentation at the SITC 2020

Read More

October 12, 2020

Change of the registered office address of Ryvu Therapeutics S.A.

Read More

September 16, 2020

First patient dosed in Europe within the Expansion Cohort of Phase I/II Clinical Study of SEL24/MEN1703

Read More

September 15, 2020

Ryvu Therapeutics 2020 H1 Financial Report

Read More

September 1, 2020

Appointment of Members of the Company’s Management and Supervisory Boards for a new term of office

Read More